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The fight against genetic diseases, whose aim is the ameli-
oration of the quality and prospect of life of the patients,
poses enormous challenges due to several well-known
issues such as the rarity of the diseases, the scarcity of
financial resources and the lack of knowledge/interest
from major stakeholders of the healthcare sector. To cope
with this complex and multifaceted problem, in 1990 a
patient association in Italy (UILDM) founded Telethon
whose mission is to advance scientific research on muscu-
lar dystrophy and all other genetic diseases with the ulti-
mate goal of paving the way for the cures. To this end,
Telethon has set an articulated strategy whose pillars are:
strategic funding of science, selection of the most promis-
ing and worthy research ideas, efficient management of
funded projects and exploitation of research results.
Indeed, in 22 years of activity, Telethon has invested about
354 million Euros, funding 2,375 projects on more than
450 genetic diseases. Notably, Telethon research spans all
steps of the research path from the most basic and preli-
minary phases to the clinical translation, and is increasing
our understanding of many genetic diseases, as demon-
strated by a wealth of high impact publications. Moreover,
clinical trials for different diseases are on-going or in the
process to start.
This strategy has demonstrated itself as effective in
advancing biomedical research; nonetheless, it is clear that
the completion of the path to make therapies available to
the patients requires resources and expertise that are
beyond Telethon’s capacity and that typically reside within
the competence of the pharmaceutical industry. This
awareness has recently led Telethon to sign an agreement
with a major pharmaceutical company that will allow gene
therapies, performed at the San Raffaele-Telethon Institute
for Gene Therapy, to enter the last phases of the develop-
mental process for seven different genetic diseases.
The success of this agreement set the course of what
is acclaimed as “collaborative model” in the field of rare
diseases.
To date, there are several basic or pre-clinical research
projects in Telethon’s portfolio that constitute a reservoir
of ideas and knowledge on many different genetic diseases
and deserve exploitation. In this perspective, partnerships
with pharmaceutical industries and with other stake-
holders will not only lead to the completion of the path
for the most advanced research projects but also free-up
resources to be invested in research activities at earlier
stages of development, thus feeding a virtuous circle.
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